TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03111238
Drug: REX-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: REX-001 is administered through an intra-arterial catheter.
Study: NCT03111238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered through an intra-arterial catheter.
Study: NCT00871767
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet (Test formulation)
Study: NCT00871767
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet (Reference formulation)
Study: NCT00871767
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet (Test formulation)
Study: NCT00871767
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (2 x 50 mg tablet (Reference Formulation)
Study: NCT02872116
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT02872116
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT02872116
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT01792700
Drug: tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03901144
Drug: 2% urea/20% glycerol cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing cream for topical application
Study: NCT03901144
Drug: Miniderm® 20% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturizing cream for topical application
Study: NCT03901144
Drug: Diprobase® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient cream for topical application
Study: NCT02952365
Drug: Tissue sealant
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of tissue sealant on eyes undergoing LASIK enhancement
Study: NCT00128895
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine 2 mg/kg oral once daily, duration according to arm
Study: NCT03413124
Drug: MGL-3196 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGL-3196 in Tablet form
Study: NCT02852681
Drug: 15 mg E4/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
Study: NCT03413124
Drug: MGL-3196 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGL-3196 in Capsule form
Study: NCT01329627
Drug: Paclitaxel/doxorubicin/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Study: NCT00736853
Drug: Tramadol Hydrochloride Plus Acetaminophen (Open-Label)
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
Study: NCT00736853
Drug: Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
Study: NCT01329627
Drug: Paclitaxel/doxorubicin/cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Study: NCT00551876
Drug: Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01528930
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg, once daily for 2 years
Study: NCT02202395
Drug: LTS 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: use LTS 0.5mg/d
Study: NCT02202395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: use placebo once daily
Study: NCT01484210
Drug: Elpenhaler active - Diskus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
Study: NCT02202239
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
Study: NCT02202239
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be injected continuously during maintenance of anesthesia.
Study: NCT06051786
Drug: Dymista™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
Study: NCT02763839
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Study: NCT02763839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
Study: NCT02763839
Drug: Sinemet 25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
Study: NCT00431626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before and after treatment of TURP
Study: NCT01104896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
Study: NCT00395603
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01903798
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid
Study: NCT00485017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules daily in a.m. and in p.m. for 24 weeks
Study: NCT02899936
Drug: 3 drug dose - IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study: NCT01276262
Drug: Microgynon® 30 (Oral contraceptive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, repeated doses
Study: NCT01276262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets BID, repeated doses for 21 days
Study: NCT00174902
Drug: inderal (drug), acetylsalicylic acid (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00702845
Drug: recFSH (follitropin beta)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recFSH SC injection
Study: NCT00702845
Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Study: NCT00461747
Drug: VBMCP/VBAD/Velcade
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20.
Study: NCT02139943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule will be taken orally, before the first meal of the day.
Study: NCT04120597
Drug: Zishen Qingre Lishi Huayu Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Study: NCT04120597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Study: NCT02113072
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
Study: NCT02113072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
Study: NCT01041417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection
Study: NCT03087513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
Study: NCT02299375
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
Study: NCT02047981
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Study: NCT02047981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Study: NCT03077542
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: conditioning regimen
Study: NCT02569866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing placebo/500mg
Study: NCT01333293
Drug: injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections
Study: NCT01943812
Drug: Estradiol and progeterone
Normalized name: medroxyprogesterone and estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and progesterone
Study: NCT01713946
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Study: NCT01713946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Study: NCT01713946
Drug: Antiepileptic drug (1 to 3 only)
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
Study: NCT00871871
Drug: Comparator: Placebo to HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
Study: NCT00871871
Drug: Comparator: Placebo to ISMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
Study: NCT01467011
Drug: Enteric-coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1440mg/day for 6 months posttransplant
Study: NCT01875159
Drug: Caffeine citrate 6 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
Study: NCT00908453
Drug: fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
Study: NCT04480840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03864939
Drug: dHAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
Study: NCT03864939
Drug: No dHAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
Study: NCT02219646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo two tablets daily for 6 months
Study: NCT00866203
Drug: HDS vs ProMECE/CytaBOM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00032669
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03707509
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum 6 cycles for combined therapy.
Study: NCT05241509
Drug: Cymbopogon citratus (lemongrass) oil gel
Normalized name: CYMBOPOGON CITRATUS LEAF OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
Study: NCT04398511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges after breakfast, lunch and dinner for 21 days.
Study: NCT00637065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tables - identical to active drug but without the active ingredient -
Study: NCT00823186
Drug: Phyxol(Paclitaxel)
Normalized name: phytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine
Study: NCT00629863
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00527735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
Study: NCT01545726
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 was supplied as capsules for oral administration.
Study: NCT01545726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as capsules for oral administration.
Study: NCT02122679
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03014947
Drug: MSB11022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
Study: NCT03014947
Drug: US-licensed Humira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
Study: NCT03014947
Drug: EU-approved Humira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
Study: NCT01094613
Drug: Delayed Release 6 mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.
Study: NCT01094613
Drug: 6 Mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
Study: NCT02431988
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
Study: NCT02211053
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg IV bolus + 10 mg/h infusion
Study: NCT02211053
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687361
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00791388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, 2x/day for 14 days
Study: NCT03902691
Drug: ESPO
Normalized name: Espotabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
Study: NCT00671034
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00671034
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00671034
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00671034
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, IT, or PO
Study: NCT00330759
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
Study: NCT00997035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
Study: NCT02863614
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02863614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00930891
Drug: Standard Chemotherapy (PCDE or PE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles
Study: NCT00930891
Drug: Experimental Treatment (PCDE or PE + bevacizumab)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
Study: NCT00914186
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion